Response to comment on 'Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity'.
| Autor: | Goldhamer DJ; Department of Molecular and Cell Biology, University of Connecticut, Storrs, United States., Lees-Shepard JB; Department of Molecular and Cell Biology, University of Connecticut, Storrs, United States. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | ELife [Elife] 2019 Jan 30; Vol. 8. Date of Electronic Publication: 2019 Jan 30. |
| DOI: | 10.7554/eLife.43928 |
| Abstrakt: | We respond to concerns expressed by Pacifici and Shore (2019) about a recent paper (Lees-Shepard and Goldhamer, 2018a) in which we reported that the drug palovarotene can have severe side effects in a mouse model of fibrodysplasia ossificans progressiva. Competing Interests: DG No competing interests declared, JL is currently a scientist at Regeneron Pharmaceuticals, who are currently conducting trials for a drug treatment for FOP. The work reported in Lees-Shepard et al. (2018a), as well as the preliminary data noted above, was conducted entirely at the University of Connecticut and was completed more than a year before he accepted his position at Regeneron. (© 2019, Goldhamer and Lees-Shepard.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|